The company's strategic focus on NDA filing, market access, and commercialization planning for lorundrostat indicates a positive outlook. The Q&A reveals confidence in payer engagement and differentiation strategies, despite some uncertainties in commercial specifics. The positive clinical data and emphasis on significant unmet needs in hypertension further support a positive sentiment. However, the lack of specific details in some responses and the short duration of the Phase II OSA study may temper expectations slightly, but overall, the sentiment remains positive.